Core Insights - Oculis Holding AG has appointed Mark Kupersmith, M.D. as Chief Medical Advisor for Neuro-Ophthalmology and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisor for Ophthalmology, enhancing its leadership team during a critical phase of development [1][3][4] Company Developments - Oculis has made significant progress in its clinical pipeline, completing enrollment in Phase 3 DIAMOND trials for OCS-01 targeting diabetic macular edema and aligning with the U.S. FDA on a genotype-based development program for Licaminlimab (OCS-02) in dry eye disease [2][4] - Positive topline results were announced for Privosegtor (OCS-05) in acute optic neuritis, marking a pivotal advancement in neuroprotection therapies [2][6] Leadership Expertise - Mark Kupersmith, M.D. brings over 40 years of experience in neuro-ophthalmology, contributing critical expertise to Oculis' expansion into this field, particularly with the advancements in Privosegtor [3][6] - Sebastian Wolf, M.D., Ph.D. is recognized for his extensive background in retina and imaging, which will support the execution of the DIAMOND program and the development of OCS-01 [4][10] Clinical Pipeline - Oculis' pipeline includes three core product candidates: OCS-01 for diabetic macular edema, Privosegtor (OCS-05) for acute optic neuritis, and Licaminlimab (OCS-02) for dry eye disease, all addressing significant unmet medical needs [13]